Sensory NeuroStimulation Inc. Announces Issuance of U.S. Patent for Relaxis™, the First and Only FDA-Cleared Non-Drug Treatment to Improve Sleep for Patients with Restless Legs Syndrome

SAN CLEMENTE, Calif.--()--Sensory NeuroStimulation Inc., a pioneer of non-pharmacological treatments for RLS (Restless Legs Syndrome), announced today that the United States Patent and Trademark Office has issued U.S. Patent 9,017,273 to the company covering the technologies used in RelaxisTM, a vibratory medical device that helps improve the quality of sleep in patients with primary RLS.

The patent, entitled “Devices and Methods for Treating Restless Leg Syndrome,” claims an exemplary system for generating a counter-stimulation in a patient suffering from RLS and includes a device configured and arranged to generate a counter-stimulation of an amplitude, intensity, and time duration sufficient to relieve RLS. These patent rights are assigned to and wholly owned by Sensory NeuroStimulation Inc. The patent will expire in 2035.

Relaxis is the first and only medical device cleared by the FDA for improving the quality of sleep for patients with primary RLS.

A person with RLS often experiences uncomfortable, uncontrollable tingling, aching, and dysphoria in their legs, which typically begin while a person is at rest, about to go to sleep, or already asleep. Repeated sleep interruptions from RLS can reduce a patient’s quality of life, leading to physical fatigue, reduced mental functioning, and emotional stress. In severe cases, RLS attacks may occur several times and with increased severity during the night.

“The proprietary Relaxis pad provides vibratory counterstimulation through unique vibratory frequencies and is the only technology that was specifically designed to address the symptoms of Restless Legs Syndrome,” said Fred Burbank, M.D., CEO of Sensory NeuroStimulation, Relaxis’ inventor and former RLS sufferer.

The results of two prospective, double blinded, randomized, controlled, multi-center clinical trials validated the ability of this technology to improve the quality of sleep in patients with primary RLS. During an RLS episode, the patient places the low-profile Relaxis pad at the site of their discomfort and chooses a vibration intensity that is pleasant and strong enough to displace the unpleasant sensations of RLS. The device provides 30 minutes of vibratory counterstimulation, gradually ramping down and shutting off without waking the patient. The soothing vibratory counterstimulation provides relief that is similar to what patients get from massaging their legs.

The Relaxis device is available nationwide on a prescription basis only. For more information about the Relaxis device, visit http://myrelaxis.com.

About Sensory NeuroStimulation Inc.

Based in San Clemente, Calif., the privately held Sensory NeuroStimulation Inc. was formed in 2009 after the company’s CEO, Fred Burbank, M.D., began experiencing RLS and sought a mechanical solution to relieving the condition’s symptoms. Sensory NeuroStimulation assembles RelaxisTM, the first FDA-approved non-drug medical device that can improve the quality of sleep in patients with primary Restless Legs Syndrome (RLS).

Trademark Statement: Relaxis is a trademark of Sensory NeuroStimulation, Inc.

Contacts

LMJPR
Carol Perng, 310-720-8526
carolperng@gmail.com

Release Summary

U.S. Patent & Trademark Office has granted a patent to Sensory NeuroStimulation Inc. for Relaxis, the first and only FDA-cleared, non-drug treatment for Restless Legs Syndrome (RLS).

Contacts

LMJPR
Carol Perng, 310-720-8526
carolperng@gmail.com